Clinical Trials Logo

Choroidal Neovascularization clinical trials

View clinical trials related to Choroidal Neovascularization.

Filter by:

NCT ID: NCT00433017 Terminated - Clinical trials for Macular Degeneration

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Start date: May 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration

NCT ID: NCT00395057 Terminated - Clinical trials for Age-Related Macular Degeneration

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration

NCT ID: NCT00347906 Terminated - Clinical trials for Age-Related Macular Degeneration

Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD)

Start date: November 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effect of PDT and TTT for the treatment of subfoveal occult CNV in age-related macular degeneration.

NCT ID: NCT00333476 Terminated - Clinical trials for Macular Degeneration

A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Start date: May 2006
Phase: Phase 2
Study type: Interventional

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

NCT ID: NCT00327470 Terminated - Clinical trials for Macular Degeneration

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

PERSPECTIVES
Start date: July 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.

NCT ID: NCT00272766 Terminated - Clinical trials for Choroidal Neovascularization

Macugen for Histoplasmosis

Start date: February 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).

NCT ID: NCT00139282 Terminated - Clinical trials for Wet Age-Related Macular Degeneration

A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration

Start date: June 2005
Phase: Phase 3
Study type: Interventional

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older in the Western world. AMD presents in two different types: "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will evaluate the safety and efficacy of Squalamine lactate in the treatment of AMD in patients, the exact number of which will be determined based on data from the sponsor's ongoing Phase 2 trials. The trial objective is to evaluate the safety and efficacy of two doses of Squalamine lactate for Injection administered as intravenous infusions weekly for 4 weeks followed by maintenance doses every 4 weeks through week 104 compared with the safety and efficacy in the control group.

NCT ID: NCT00102115 Terminated - Clinical trials for Macular Degeneration

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Start date: December 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).

NCT ID: NCT00090532 Terminated - Clinical trials for Age-Related Macular Degeneration

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.